Chimeric antigen receptor therapy for cancer

Annual Review of Medicine

Volumn 65, Issue , 2014, Pages 333-347

  Barrett, David M ^a   Singh, Nathan ^a   Porter, David L ^a   Grupp, Stephan A ^a   June, Carl H ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Adoptive transfer; Chimeric antigen receptor; Gene transfer; Synthetic biology; T cell receptor

Indexed keywords

CANCER VACCINE; CHIMERIC ANTIGEN RECEPTOR; LYMPHOCYTE ANTIGEN RECEPTOR; MEMBRANE ANTIGEN; UNCLASSIFIED DRUG;

ADOPTIVE TRANSFER; ALLOGENEIC STEM CELL TRANSPLANTATION; ANTINEOPLASTIC ACTIVITY; B CELL LYMPHOMA; CANCER IMMUNOTHERAPY; CELL ENGINEERING; CELL TRANSFER; CHILDHOOD CANCER; CHRONIC LYMPHATIC LEUKEMIA; CYTOTOXIC T LYMPHOCYTE; DRUG CYTOTOXICITY; DRUG TARGETING; HISTORY OF MEDICINE; HUMAN; LYMPHOCYTE TRANSFER; MOLECULARLY TARGETED THERAPY; NEOPLASM; NEUROBLASTOMA; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; SYNTHETIC BIOLOGY; T CELL CULTURE; T LYMPHOCYTE; TUMOR ASSOCIATED LEUKOCYTE;

ADOPTIVE TRANSFER; CELL ENGINEERING; HUMANS; IMMUNOTHERAPY; LYMPHOCYTES, TUMOR-INFILTRATING; NEOPLASMS; RECEPTORS, ANTIGEN, T-CELL; T-LYMPHOCYTES, CYTOTOXIC;

EID: 84893562519     PISSN: 00664219     EISSN: 1545326X     Source Type: Book Series    
DOI: 10.1146/annurev-med-060512-150254     Document Type: Review

References (92)

1. Mitchison NA. 1955. Studies on the immunological response to foreign tumor transplants in the mouse. I. The role of lymph node cells in conferring immunity by adoptive transfer. J. Exp. Med. 102:157-77
2. Barnes DW, Ford CE, Ilbery PL, et al. 1957. Tissue transplantation in the radiation chimera. J. Cell. Physiol. Suppl. 50:123-38
3. Barnes DW, Loutit JF. 1957. Treatment of murine leukaemia with x-rays and homologous bone marrow. II. Br. J. Haematol. 3:241-52
4. Mathe G, Amiel JL, Schwarzenberg L, et al. 1965. Adoptive immunotherapy of acute leukemia: experimental and clinical results. Cancer Res. 25:1525-31
5. Rosenberg SA, Terry WD. 1977. Passive immunotherapy of cancer in animals and man. Adv. Cancer Res. 25:323-88
6. Weiden PL, Flournoy N, Thomas ED, et al. 1979. Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. N. Engl. J. Med. 300:1068-73
7. Klebanoff CA, Khong HT, Antony PA, et al. 2005. Sinks, suppressors and antigen presenters: how lymphodepletion enhances T cell-mediated tumor immunotherapy. Trends Immunol. 26:111-17
8. Dummer W, Niethammer AG, Baccala R, et al. 2002. T cell homeostatic proliferation elicits effective antitumor autoimmunity. J. Clin. Invest. 110:185-92
9. Hinrichs C, Borman Z, Cassard L, et al. 2009. Adoptively transferred effector cells derived from naive rather than central memory CD8 T cells mediate superior antitumor immunity. Proc. Natl. Acad. Sci. USA 106:17469-74
10. Berger C, Jensen MC, Lansdorp PM, et al. 2008. Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates. J. Clin. Invest. 118:294-305
11. Paulos CM, Carpenito C, Plesa G, et al. 2010. The inducible costimulator ICOS is critical for the development of human TH17 cells. Sci. Transl. Med. 2:55-78
12. Gattinoni L, Lugli E, Ji Y, et al. 2011. A human memory T cell subset with stem cell-like properties. Nat. Med. 17:1290-97
13. Lee JC, Hayman E, Pegram HJ, et al. 2011. In vivo inhibition of human CD19-targeted effector T cells by natural T regulatory cells in a xenotransplant murine model of B cell malignancy. Cancer Res. 71:2871-81
14. Zhou J, Shen X, Huang J, et al. 2005. Telomere length of transferred lymphocytes correlates with in vivo persistence and tumor regression in melanoma patients receiving cell transfer therapy. J. Immunol. 175:7046-52 (Pubitemid 41598952)
15. Weng NP, Levine BL, June CH, et al. 1996. Regulated expression of telomerase activity in human T lymphocyte development and activation. J. Exp. Med. 183:2471-80
16. Chen ML, Pittet MJ, Gorelik L, et al. 2005. Regulatory T cells suppress tumor-specific CD8 T cell cytotoxicity through TGF-βsignals in vivo. Proc. Natl. Acad. Sci. USA 102:419-24
17. Loskog A, Giandomenico V, Rossig C, et al. 2006. Addition of the CD28 signaling domain to chimeric T-cell receptors enhances chimeric T-cell resistance to T regulatory cells. Leukemia 20:1819-28 (Pubitemid 44574993)
18. Kalos M, Levine BL, Porter DL, et al. 2011. T cells expressing chimeric receptors establish memory and potent antitumor effects in patients with advanced leukemia. Sci. Transl. Med. 3:95-73
19. Porter DL, Levine BL, Kalos M, et al. 2011. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N. Engl. J. Med. 365:725-33
20. Zhao Y, Moon E, Carpenito C, et al. 2010. Multiple injections of electroporated autologous T cells expressing a chimeric antigen receptor mediate regression of human disseminated tumor. Cancer Res. 70:9062-72
21. Barrett DM, Zhao Y, Liu X, et al. 2011. Treatment of advanced leukemia in mice with mRNA engineered T cells. Hum. Gene Ther. 22:1575-86
22. Seder RA, Darrah PA, Roederer M. 2008. T-cell quality in memory and protection: implications for vaccine design. Nat. Rev. Immunol. 211:58-66
23. Levine BL, Bernstein W, Craighead N, et al. 1997. Effects of CD28 costimulation on long term proliferation of CD4+ T cells in the absence of exogenous feeder cells. J. Immunol. 159:5921-30 (Pubitemid 127471527)
24. Maus MV, Kovacs B, Kwok WW, et al. 2004. Extensive replicative capacity of human central memory T cells. J. Immunol. 172:6675-83 (Pubitemid 38669103)
25. Zhang H, Snyder K, Suhoski MM, et al. 2007. 4-1BB is superior to CD28 costimulation for generating CD8+ cytotoxic lymphocytes for adoptive immunotherapy. J. Immunol. 179:4910-18
26. Turtle C, Swanson H, Fujii N, et al. 2009. A distinct subset of self-renewing human memory CD8+ T cells survives cytotoxic chemotherapy. Immunity 31:834-44
27. June CH, Blazar BR, Riley JL. 2009. Engineering lymphocyte subsets: tools, trials and tribulations. Nat. Rev. Immunol. 9:704-16
28. Miller AD, Rosman GJ. 1989. Improved retroviral vectors for gene transfer and expression. Biotechniques 7:980-90 (Pubitemid 19262578)
29. Naldini L, Blomer U, Gallay P, et al. 1996. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 272:263-67
30. Su Z, Dannull J, Yang BK, et al. 2005. Telomerase mRNA-transfected dendritic cells stimulate antigenspecific CD8+ and CD4+ T cell responses in patients with metastatic prostate cancer. J. Immunol. 174:3798-807 (Pubitemid 40354093)
31. Chen YY, Galloway KE, Smolke CD. 2012. Synthetic biology: advancing biological frontiers by building synthetic systems. Genome Biol. 13:240
32. Hacein-Bey-Abina S, Garrigue A, Wang GP, et al. 2008. Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J. Clin. Invest. 118:3132-42
33. Muul LM, Tuschong LM, Soenen SL, et al. 2003. Persistence and expression of the adenosine deaminase gene for 12 years and immune reaction to gene transfer components: long-term results of the first clinical gene therapy trial. Blood 101:2563-69 (Pubitemid 36857614)
34. Scholler J, Brady T, Binder-Scholl G, et al. 2012. Decade-long safety and function of retroviral-modified chimeric antigen receptor T cells. Sci. Transl. Med. 4:132ra53
35. Dudley ME, Yang JC, Sherry R, et al. 2008. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J. Clin. Oncol. 26:5233-39
36. Teshima T, Liu C, Lowler KP, et al. 2002. Donor leukocyte infusion from immunized donors increases tumor vaccine efficacy after allogeneic bone marrow transplantation. Cancer Res. 62:796-800 (Pubitemid 34126956)
37. Mori S, Kocak U, Shaw JL, et al. 2005. Augmentation of post transplant immunity: antigen encounter at the time of hematopoietic stem cell transplantation enhances antigen-specific donor T-cell responses in the post transplant repertoire. Bone Marrow Transplant. 35:793-801 (Pubitemid 40613787)
38. Wang LX, Shu SY, Plautz GE. 2005. Host lymphodepletion augments T cell adoptive immunotherapy through enhanced intratumoral proliferation of effector cells. Cancer Res. 65:9547-54 (Pubitemid 41508025)
39. Sumegi J, Nestheide SV, Barnes MG, et al. 2013. Gene expression signatures differ between different clinical forms of familial hemophagocytic lymphohistiocytosis. Blood 121:e14-24
40. Grupp SA, Prak EL, Boyer J, et al. 2012. Adoptive transfer of autologousTcells improvesTcell repertoire diversity and long term B cell function in pediatric patients with neuroblastoma. Clin. Cancer Res. 18:6732- 41
41. Rapoport AP, Aqui NA, Stadtmauer EA, et al. 2011. Combination immunotherapy using adoptive T-cell transfer and tumor antigen vaccination on the basis of hTERT and survivin after ASCT for myeloma. Blood 117:788-97
42. Krause A, Guo HF, Latouche JB, et al. 1998. Antigen-dependent CD28 signaling selectively enhances survival and proliferation in genetically modified activated human primary T lymphocytes. J. Exp. Med. 188:619-26
43. Charo J, Finkelstein SE, Grewal N, et al. 2005. Bcl-2 overexpression enhances tumor-specific T-cell survival. Cancer Res. 65:2001-8 (Pubitemid 40478630)
44. Kerkar SP, Goldszmid RS, Muranski P, et al. 2011. IL-12 triggers a programmatic change in dysfunctional myeloid-derived cells within mouse tumors. J. Clin. Invest. 121:4746-57
45. Cheng LE, Ohlen C, Nelson BH, et al. 2002. Enhanced signaling through the IL-2 receptor in CD8+ T cells regulated by antigen recognition results in preferential proliferation and expansion of responding CD8+ T cells rather than promotion of cell death. Proc. Natl. Acad. Sci. USA 99:3001-6
46. Moon E, Carpenito C, Sun J, et al. 2011. Functional CCR2 receptor enhances tumor localization and eradication by human T cells expressing a mesothelin-specific chimeric antibody receptor. Clin. Cancer Res. 17:4719-30
47. Eshhar Z, Waks T, Bendavid A, et al. 2001. Functional expression of chimeric receptor genes in human T cells. J. Immunol. Methods 248:67-76 (Pubitemid 32167025)
48. Krause A, Guo HF, Latouche JB, et al. 1998. Antigen-dependent CD28 signaling selectively enhances survival and proliferation in genetically modified activated human primary T lymphocytes. J. Exp. Med. 188:619-26
49. Milone MC, Fish JD, Carpenito C, et al. 2009. Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo. Mol. Ther. 17:1453-64
50. Till BG, JensenMC, Wang J, et al. 2012. CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results. Blood 119:3940- 50
51. Deeks SG, Wagner B, Anton PA, et al. 2002. A phase II randomized study of HIV-specific T-cell gene therapy in subjects with undetectable plasma viremia on combination anti-retroviral therapy. Mol. Ther. 5:788-97
52. Kershaw MH, Westwood JA, Parker LL, et al. 2006. A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin. Cancer Res. 12:6106-15
53. Park JR, DiGiusto DL, Slovak M, et al. 2007. Adoptive transfer of chimeric antigen receptor re-directed cytolytic T lymphocyte clones in patients with neuroblastoma. Mol. Ther. 15:825-33
54. Lamers CH, Sleijfer S, Vulto AG, et al. 2006. Treatment ofmetastatic renal cell carcinomawith autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience. J. Clin.Oncol. 24:e20-22
55. Di Stasi A, Tey SK, Dotti G, et al. 2011. Inducible apoptosis as a safety switch for adoptive cell therapy. N. Engl. J. Med. 365:1673-83
56. Jensen M, Popplewell L, Cooper L, et al. 2010. Anti-transgene rejection responses contribute to attenuated persistence of adoptively transferred CD20/CD19-specific chimeric antigen receptor re-directed T cells in humans. Biol. Blood Marrow Transplant. 16:1245-56
57. Lamers C, Willemsen R, van Elzakker P, et al. 2011. Immune responses to transgene and retroviral vector in patients treated with ex vivo engineered T cells. Blood 117:72-82
58. Louis CU, Savoldo B, Dotti G, et al. 2011. Anti-tumor activity and long-term fate of chimeric antigen receptor positive T-cells in patients with neuroblastoma. Blood 118:6050-56
59. Bretscher P, Cohn M. 1970. A theory of self-nonself discrimination. Science 169:1042-49
60. BrockerT. 2000. Chimeric Fv-xi or Fv-epsilon receptors are not sufficient to induce activation or cytokine production in peripheral T cells. Blood 96:1999-2001
61. Finney HM, Lawson ADG, Bebbington CR, et al. 1998. Chimeric receptors providing both primary and costimulatory signaling in T cells from a single gene product. J. Immunol. 161:2791-97 (Pubitemid 28425698)
62. Imai C, Mihara K, Andreansky M, et al. 2004. Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia. Leukemia 18:676-84 (Pubitemid 38500185)
63. Finney HM, Akbar AN, Lawson ADG. 2004. Activation of resting human primary T cells with chimeric receptors: costimulation from CD28, inducible costimulator, CD134, and CD137 in series with signals from the TCR zeta chain. J. Immunol. 172:104-13 (Pubitemid 38020461)
64. Song D-G, Ye Q, Poussin M, et al. 2012. CD27 costimulation augments the survival and antitumor activity of redirected human T cells in vivo. Blood 119:696-706
65. Kohn DB, Dotti G, Brentjens R, et al. 2011. CARS on track in the clinic: report of a meeting organized by the Blood and Marrow Transplant Clinical Trials Network (BMT CTN) sub-committee on cell and gene therapy, Washington, DC, May 18, 2010. Mol. Ther. 19:432-38
66. Jena B, Dotti G, Cooper L. 2010. Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor. Blood 116:1035-44
67. Kochenderfer J, Wilson W, Janik J, et al. 2010. Eradication of B-lineage cells and regression of lymphoma in a patient treatedwith autologousTcells genetically-engineered to recognize CD19. Blood 116:4099-102
68. Kochenderfer JN, Dudley ME, Feldman SA, et al. 2012. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptortransduced T cells. Blood 119:2709-20
69. Brentjens R, Riviére I, Park J, et al. 2011. Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood 118:4817-28
70. Savoldo B, Ramos CA, Liu E, et al. 2011. CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. J. Clin. Invest. 121:1822-25
71. Grupp SA, KalosM, Barrett D, et al. 2013. Chimeric antigen receptor-modifiedTcells for acute lymphoid leukemia. N. Engl. J. Med. 368:1509-18
72. Kebriaei P, Huls H, Jena B, et al. 2012. Infusing CD19-directed T cells to augment disease control in patients undergoing autologous hematopoietic stem-cell transplantation for advanced B-lymphoid malignancies. Hum. Gene Ther. 23:444-50
73. Di Stasi A, Tey SK, Dotti G, et al. 2011. Inducible apoptosis as a safety switch for adoptive cell therapy. N. Engl. J. Med. 365:1673-83
74. Zhao Y, Moon E, Carpenito C, et al. 2010. Multiple injections of electroporated autologous T cells expressing a chimeric antigen receptor mediate regression of human disseminated tumor. Cancer Res. 70:9053-61
75. Birkholz K, Hombach A, Krug C, et al. 2009. Transfer ofmRNAencoding recombinant immunoreceptors reprograms CD4+ and CD8+ T cells for use in the adoptive immunotherapy of cancer. Gene Ther. 16:596-604
76. Almasbak H, Rian E, Hoel HJ, et al. 2011. Transiently redirected T cells for adoptive transfer. Cytotherapy 13:629-40
77. Yoon SH, Lee JM, Cho HI, et al. 2009. Adoptive immunotherapy using human peripheral blood lymphocytes transferred with RNA encoding Her-2/neu-specific chimeric immune receptor in ovarian cancer xenograft model. Cancer Gene Ther. 16:489-97
78. Rabinovich PM, Komarovskaya ME, Wrzesinski SH, et al. 2009. Chimeric receptor mRNA transfection as a tool to generate antineoplastic lymphocytes. Hum. Gene Ther. 20:51-61
79. Heslop HE, Rooney CM. 1997. Adoptive cellular immunotherapy for EBV lymphoproliferative disease. Immunol. Rev. 157:217-22
80. Kernan NA, CollinsNH, Juliano L, et al. 1986. Clonable T lymphocytes in T cell-depleted bone marrow transplants correlate with development of graft-v-host disease. Blood 68:770-73 (Pubitemid 16008184)
81. Cairo MS, Coiffier B, Reiter A, et al. 2010. Recommendations for the evaluation of risk and prophylaxis of tumour lysis syndrome (TLS) in adults and children with malignant diseases: an expert TLS panel consensus. Br. J. Haematol. 149:578-86
82. Bear AS, Morgan RA, Cornetta K, et al. 2012. Replication-competent retroviruses in gene-modified T cells used in clinical trials: Is it time to revise the testing requirements? Mol. Ther. 20:246-49
83. Alyea EP, DeAngelo DJ, Moldrem J, et al. 2010. NCI First International Workshop on the Biology, Prevention and Treatment of Relapse after Allogeneic Hematopoietic Cell Transplantation: report from the committee on prevention of relapse following allogeneic cell transplantation for hematologic malignancies. Biol. Blood Marrow Transplant. 16:1037-69
84. Porter DL, Levine BL, Bunin N, et al. 2006. A phase I trial of donor lymphocyte infusions expanded and activated ex-vivo via CD3/CD28 co-stimulation. Blood 107:1325-31 (Pubitemid 43242365)
85. Yee C, Thompson JA, Byrd D, et al. 2002. Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells. Proc. Natl. Acad. Sci. USA 99:16168-73
86. Mitsuyasu RT, Anton PA, Deeks SG, et al. 2000. Prolonged survival and tissue trafficking following adoptive transfer of CD4zeta gene-modified autologous CD4+ and CD8+T cells in human immunodeficiency virus-infected subjects. Blood 96:785-93 (Pubitemid 30616838)
87. Zhang H, Chua KS, Guimond M, et al. 2005. Lymphopenia and interleukin-2 therapy alter homeostasis of CD4+CD25+ regulatory T cells. Nat. Med. 11:1238-43
88. Ku CC, Murakami M, Sakamoto A, et al. 2000. Control of homeostasis of CD8+ memory T cells by opposing cytokines. Science 288:675-78 (Pubitemid 30241571)
89. Berger C, Berger M, Hackman RC, et al. 2009. Safety and immunologic effects of IL-15 administration in nonhuman primates. Blood 114:2417-26
90. Dudley ME, Wunderlich JR, Robbins PF, et al. 2002. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 298:850-54 (Pubitemid 35231542)
91. Laport GG, Levine BL, Stadtmauer EA, et al. 2003. Adoptive transfer of costimulated T cells induces lymphocytosis in patients with relapsed/refractory non-Hodgkin lymphoma following CD34+-selected hematopoietic cell transplantation. Blood 102:2004-13 (Pubitemid 37122373)
92. Rapoport AP, Stadtmauer EA, Aqui N, et al. 2009. Rapid immune recovery and graft-versus-host diseaselike engraftment syndrome following adoptive transfer of costimulated autologous T cells. Clin. Cancer Res. 15:4499-507